ADMA Biologics Executive and Directors Compensation Adjustments for 2025

Delaware-incorporated company ADMA Biologics Inc., a leading provider of innovative plasma-derived biopharmaceuticals, has reported an amendment to the annual equity grant policy as well as changes to the compensation of selected members of its executive team, according to an 8-K filing with the U.S Securities and Exchange Commission.

As per the document, the company’s Board of Directors approved the executive compensation changes on February 19, 2025, following recommendations from the Compensation Committee.

The report disclosed that the base salaries for 2025, cash bonus for 2024 performance, and annual incentive awards have been approved for Adam S. Grossman, the company’s President and Chief Executive Officer, Kaitlin Kestenberg, the Chief Operating Officer and Senior Vice President, Compliance, and Brad Tade, the company’s Chief Financial Officer and Treasurer. Grossman’s compensation package includes a base salary of $925,000, a cash bonus of $1,020,000, 252,022 restricted stock units (RSUs), and 376,744 shares underlying stock options. Individually, Kestenberg and Tade will receive base salaries of $575,000 and $500,000 and cash bonuses of $293,625 and $254,475 respectively.

All executives’ RSUs will vest over four years, and their stock options will vest 25% on the one-year anniversary of the grant date and then monthly over three years, becoming fully vested on February 19, 2029.

Boosts to compensation align with the achievement of the company’s 2024 corporate goals and milestones and each executive officer’s contribution, set forth by the Compensation Committee. The RSUs and stock options were awarded after evaluating the performance of the above-mentioned executive officers.

For non-employee directors, the board approved an amendment to the annual equity grant policy. Moving forward, they will receive annual equity grants amounting to $350,000 of long-term incentive value. The awards will comprise 50% as RSUs and 50% as options to purchase Common Stock and will be priced at the same time as annual executive officer grants of equity awards.

On February 19, 2025, an increase in retainers for chairpersons and members of the board’s committees was also sanctioned. The raise will be effective from January 1, 2025. Non-employee directors will continue to receive an annual cash retainer of $50,000, while the chairman and vice chairman will each receive an additional annual cash retainer of $40,000.

The adjustments were part of the company’s efforts to incentivise and reward the contributions of its executive officers and directors towards the attainment of listed corporate goals.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read ADMA Biologics’s 8K filing here.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.